Mechanisms of enhanced oral availability of CYP3A4 substrates by grapefruit constituents: Decreased enterocyte CYP3A4 concentration and mechanism-based inactivation by furanocoumarins

Drug Metabolism and Disposition

Volumn 25, Issue 11, 1997, Pages 1228-1233

  Schmiedlin Ren, Phyllissa ^b   Edwards, David J ^b   Fitzsimmons, Michael E ^b   He, Kan ^b   Lown, Kenneth S ^b   Woster, Patrick M ^b   Rahman, Atiqur ^b   Thummel, Kenneth E ^b   Fisher, Jeannine M ^b   Hollenberg, Paul F ^b   Watkins, Paul B ^a  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; FUROCOUMARIN; INTESTINE ENZYME; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INACTIVATION; FRUIT JUICE; GRAPE; PRIORITY JOURNAL; SMALL INTESTINE MUCOSA;

BIOLOGICAL AVAILABILITY; CACO-2 CELLS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CITRUS; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ESCHERICHIA COLI; HUMANS; IMMUNOBLOTTING; INTESTINAL MUCOSA; MICROSOMES; MIXED FUNCTION OXYGENASES; PSORALENS;

CITRUS X PARADISI; VITIS SP.;

EID: 0030696487     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. M. P. Ducharme, L. H. Warbasse, and D. J. Edwards: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin. Pharmacol. Ther. 57, 485-491 (1995).
2. D. G. Bailey, J. M. O. Arnold, J. R. Bend, L. T. Tran, and J. D. Spence: Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br. J. Clin. Pharmacol. 40, 135-140 (1995).
3. H. H. T. Kupferschmidt, H. R. Ha, W. H. Ziegler, P. J. Meier, and S. Krähenbühl: Interaction between grapefruit juice and midazolam in humans. Clin. Pharmacol. Ther. 58, 20-28 (1995).
4. R. E. Benton, P. K. Honig, K. Zamani, L. R. Cantilena, and R. L. Woosley: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol Ther. 59, 383-388 (1996).
5. U. Fuhr, S. Harder, P. Lopez-Rojas, H. Muller-Peltzer, R. Kern, and A. H. Staib: Increase of verapamil concentrations in steady state by coadministration of grapefruit juice. Naunyn-Schmiedeberg's Arch. Pharmacol. 349, R134 (1994).
6. Saquinavir: with grapefruit juice. Posit. Aware 7, 5 (1996).
7. A. Weber, R. Jager, A. Borner, G. Klinger, R. Vollanth, K. Matthey, and A. Balogh: Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53, 41-47 (1996)
8. D. G. Bailey, J. M. O. Arnold, C. Munoz, and J. D. Spence: Grapefruit juice-felodipine interaction: Mechanism, predictability, and effect of naringin. Clin. Pharmacol. Ther. 53, 637-642 (1993).
9. F. P. Guengerich and D.-H. Kim: In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11, 2275-2279 (1990).
10. U. Fuhr and A. L. Kummert: The fate of naringin in humans: A key to grapefruit juice-drug interactions? Clin. Pharmacol. Ther. 58, 365-373 (1995).
11. A. Miniscalco, J. Lundahl, C. G. Regardh, B. Edgar, and U. G. Eriksson: Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. J. Pharmacol. Exp. Ther. 261, 1195-1199 (1992).
12. K. S. Lown, D. G. Bailey, R. J. Fontana, S. K. Janardan, C. H. Adair, L. A. Fortlage, M. B. Brown, W. Guo, and P. B. Watkins: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J. Clin. Invest. 99, 2545-2553 (1997).
13. J. Rashid, C. McKinstry, A. G. Renwick, M. Dirnhuber, D. G. Waller, and C. F. George: Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br. J. Clin. Pharmacol. 36, 460-463 (1993).
14. D. J. Edwards, F. H. Bellevue, and P. M. Woster: Identification of 6′,7′-dihydroxybergamottin, a cytochrome P450 inhibitor, in grapefruit juice. Drug Metab. Dispos. 24, 1287-1290 (1996).
15. Y. Cai, D. Bennett, R. V. Nair, O. Ceska, M. J. Ashwood-Smith, and J. DiGiovanni: Inhibition and inactivation of murine hepatic ethoxy-and pentoxyresorufin O-dealkylase by naturally occurring coumarins. Chem. Res. Toxicol. 6, 872-879 (1993).
16. P. Letteron, V. Descatoire, D. Larrey, M. Tinel, J. Geneve, and D. Pessayre: Inactivation and induction of cytochrome P-450 by various psoralen derivatives in rats. J. Pharmacol. Exp. Ther. 238, 685-692 (1986).
17. H. W. Strobel, and J. D. Dignam: Purification and properties of NADPH-cytochrome P-450 reductase. Methods Enzymol. 52, 89-96 (1978).
18. D. J. Waxman, and C. Walsh: Phenobarbital-induced rat liver cytochrome P-450. Purification and characterization of two closely related isozymic forms. J. Biol. Chem. 257, 10446-10457 (1982).
19. J. W. Harris, A. Rahman, B.-R. Kim, F. P. Guengerich, and J. M. Collins: Metabolism of taxol by human hepatic microsomes and liver slices: Participation of cytochrome P450 3A4 and an unknown P450 enzyme. Cancer Res. 54, 4026-4035 (1994).
20. A. Rahman, K. R. Korzekwa, J. Grogan, F. J. Gonzalez, and J. W. Harris: Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res. 54, 5543-5546 (1994).
21. P. Schmiedlin-Ren, K. E. Thummel, J. M. Fisher, M. F. Paine, K. S. Lown, and P. B. Watkins: Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of lalpha,25-dihydroxyvitamin D3. Mol. Pharmacol. 51, 741-754 (1997).
22. K. S. Lown, J. C. Kolars, K. E. Thummel, J. L. Barnett, K. L. Kunze, S. A. Wrighton, and P. B. Watkins: Interpatient heterogeneity in expression of CYP3A4 and CYP3A5 in small bowel. Lack of prediction by the erythromycin breath test. Drug Metab. Dispos. 22, 947-955 (1994).
23. E. M. J. Gillam, T. Baba, B.-R. Kim, S. Ohmori, and F. P. Guengerich: Expression of modified human cytochrome P450 3A4 in Escherichia coli and purification and reconstitution of the enzyme. Arch. Biochem. Biophys. 305, 123-131 (1993).
24. W. B. Sinclair: Composition of peel, rag, and seeds. In "The Grapefruit-Its Composition, Physiology, and Products," pp. 200-280. University of California, Div. of Agricultural Sciences, Berkeley, 1972.
25. C. T. Walsh: Suicide substrates, mechanism-based enzyme inactivators: recent developments. Annu. Rev. Biochem. 53, 493-535 (1984).
26. M. A. Correia, S. H. Davoll, S. A. Wrighton, and P. E. Thomas: Degradation of rat liver cytochromes P450 3A after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: characterization of the proteolytic system. Arch. Biochem. Biophys. 297, 228-238 (1992).
27. J. Lundahl, C. G. Regardh, B. Edgar, and G. Johnsson: Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur. J. Clin. Pharmacol. 49, 61-67 (1995).
28. K. G. Edwards, and J. R. Stoker: Biosynthesis of coumarin: the isomerization stage. Phytochemistry 6, 655-661 (1967).